A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
A phase 2/3 trial of Lenalidomide, Daratumumab, Dexamethasone in multiple myeloma, run by AbbVie, now recruiting.
Overview
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant is a phase 2/3 interventional study registered as NCT07095452 by AbbVie, with 660 participants planned, started 2026-01-08 and due to reach its primary completion in 2042-01. Interventions recorded: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialSafety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Shares Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Daratumumab, Dexamethasone, Lenalidomide, AbbVie (incl. ImmunoGen, Capstan).
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.